Validation data for Anti-Spike-RBD hIgG1NQ (clone CR3022)

Anti-Spike-RBD hIgG1NQ is a recombinant monoclonal antibody (mAb) featuring the variable region of the CR3022 human mAb that specifically targets the SARS-CoV and SARS-CoV-2 Spike receptor-binding domain (RBD) and a human IgG1NQ (non-glycosylated) constant region. The binding of the antibody has been validated by ELISA, using coated Spike-RBD-His fusion peptide and an Anti-hIgG1-HRP secondary antibody. Anti-βGal hIgG1 has been used as a negative control (**Figure 1**).

Binding of Anti-Spike-RBD hIgG1NQ to SARS-CoV-2 RBD

Figure 1: SARS-CoV-2 Spike-RBD-His fusion peptide (5 µg/ml) was coated on ELISA plates overnight. A 3-fold serial dilution of the Anti-Spike-RBD hIgG1NQ (red curve) or of the Anti-βGal hIgG1 control antibody (grey curve) was performed for the capture step. A HRP-labelled anti-hIgG1 antibody (1/1000 dilution) and the HRP substrate OPD (o-phenylenediamine dihydrochloride) were used for the detection step. Absorbance was read at 490 nm.